This is an aggregated industry headline. Read the full story at PharmaVoice →
Can anyone catch up to Eli Lilly?
While rivals scramble to replace lost revenue, Lilly is opening an unprecedented gap by being a "contrarian," as one expert says.
By PharmaVoice
· Jul 7, 2026
· via PharmaVoice
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Novartis is executing more layoffs at its U.S. headquarters in East Hanover, New Jersey, handing 322 employees…
The WeekFierceBiotech ↗
AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challeng…
The WeekBriefing
Vertex’s Casgevy can now treat sickle cell disease and transfusion-dependent beta thalassemia in patients aged…